GRAL Shareholder Alert: Grail, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky

Grail, Inc. (NASDAQ: GRAL) told investors its over 140,000-participant NHS-Galleri trial was designed to achieve a statistically significant reduction in Stage III and IV cancers. On February 19, 2026, the company disclosed the opposite: the primary endpoint "was not observed." GRAL shares collapsed 50.55% in a single day. Find out if you can recover your investment losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500. From a closing price of $101.53 on February 19, 2026, shares fell to $50.21 on February 20, 2026, a loss of $51.32 per share. The lead plaintiff deadline is August 4, 2026. Throughout the Class Period of May 13, 2025 through February 19, 2026, Grail's leadership made specific, quantifiable representations about the NHS-Galleri trial's trajectory: On May 13, 2025, the company announced "Positive Top-Line Results" from the prevalent screening round, reporting a PPV "substantially higher" than the 43% observed in PATHFINDER Management stated the test was "working in the real world," detecting "clinically meaningful cancers and early-stage cancers in asymptomatic adults" On August 12, 2025, Grail's Chief Scientific Officer confirmed the study's size "was set to be able to deliver a statistically significant result" on the primary endpoint of late-stage cancer reduction During the August 12, 2025 earnings call, executives promoted the NHS-Galleri readout as a "great calling card" for global expansion and described the upcoming clinical utility data as a key catalyst On October 20, 2025, management stated that PATHFINDER 2 results gave them "a lot of confidence in the performance" heading into the NHS-Galleri readout. On February 19, 2026, Grail disclosed that the "primary endpoint of statistically significant Stage III-IV reduction was not observed." The company attributed this failure, in part, to "probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately." The lawsuit contends this admission reveals the three-year trial design and screening duration were insufficient to demonstrate whether the primary endpoint was achievable, a limitation that should have been disclosed to investors rather than concealed behind repeated assurances of confidence. What Was Communicated What Actually Happened PPV "substantially higher" than 43% Detailed results withheld from investors throughout Class Period Trial "powered" to deliver statistically significant late-stage reduction Primary endpoint of Stage III-IV reduction not observed Three-year design sufficient for clinical utility Company admitted longer follow-up time was "probably" needed NHS-Galleri as a "calling card" for global expansion NHS and global partners left without the anticipated positive data PATHFINDER 2 gave "a lot of confidence" in performance Confidence did not translate to the primary endpoint. The action claims that Grail's executives possessed information from their internal review of first-round screening results that should have tempered their public confidence. By withholding detailed data under the stated rationale of protecting "integrity" of the trial, the complaint asserts defendants potentially concealed known trendlines suggesting either a longer timeline was necessary or that the probability of achieving the statistical reduction had diminished.